| Company Name: |
Energy Chemical |
| Tel: |
021-58432009 400-005-6266 |
| Email: |
marketing@energy-chemical.com |
QNSWMJYOGMUVGO-REWXTUPXSA-N manufacturers
|
| | QNSWMJYOGMUVGO-REWXTUPXSA-N Basic information |
| | QNSWMJYOGMUVGO-REWXTUPXSA-N Chemical Properties |
| | QNSWMJYOGMUVGO-REWXTUPXSA-N Usage And Synthesis |
| Uses | Trandolapril Hydrochloride is an antihypertensive. Angiotensin converting enzyme (ACE) inhibitor. | | in vivo | Trandolapril hydrochloride (3 mg/kg/day; p.o.; 7 d) reduces renal fibrosis in obstructive nephropathy in mice, by inhibiting renal interstitial matrix expression and myofibroblast activation, decreasing renal proinflammatory cytokine RANTES and TNF-α level[2].
Trandolapril hydrochloride (0.3 mg/kg/day; p.o.; 4 weeks) improves arterial mechanics in rats, prevents arterial hypertrophy, collagen and cellular fibronectin accumulation[3].
randolapril (0.3 mg/kg/day; p.o.; 4 months) exhibits a chronic anti-hypertension effects in rats, results in blood pressure decreasing[3].
Trandolapril hydrochloride (0.25 mg/kg; p.o.; twice a day; 4 months) inhibits Atherosclerosis in the Watanabe Heritable Hyperlipidemic Rabbit[4].
| Animal Model: | UUD (unilateral ureteral obstruction) model in Male CD-1 mice (18-22 g)[2] | | Dosage: | 3 mg/kg | | Administration: | Oral gavage; daily, for 7 days | | Result: | Resulted in renal interstitial matrix expression (including fibronectin, type I, and type III collagen) decreasing, and inhibited myofibroblast activation by surprising a-smooth muscle actin (a-SMA) expression, decreased the RANTES (regulated on activation, normal T cell expressed and secreted) and TNF-α level.
|
| Animal Model: | SHR model (spontaneously hypertensive rats, 4-week-old)[3] | | Dosage: | 0.3 mg/kg | | Administration: | Oral gavage; daily for 4 weeks | | Result: | Reduced collagen content in the aortic media and increased ariterial distensibility up to about 80%.
|
| Animal Model: | Watanabe heritable hyperlipidemic rabbit (3 months old)[4] | | Dosage: | 0.25 mg/kg | | Administration: | Oral gavage; twice a day; 9 months | | Result: | Decreased in atherosclerotic involvement of the intimal surface, and also decreased cholesterol content in descending thoracic aorta.
|
|
| | QNSWMJYOGMUVGO-REWXTUPXSA-N Preparation Products And Raw materials |
|